Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women with Estrogen Receptor (ER), Progesterone Receptor (PR),and HER2 negative invasive breast cancer confirmed on core biopsy.(Note: HER2 negative by FISH preferred; HER2 0 or 1+ by IHC acceptable)~* Primary tumor size 2cm or greater by physical exam or radiographic measurements.(Note: Locally advanced T4 or inflammatory breast cancer is eligible.)~* Assessment of pre-treatment axillary lymph nodal status (Note: FNA biopsy if palpable or sentinel lymph node biopsy (SLNB) if not palpable preferred; clinical exam acceptable.)~* Absolute neutrophil count \> 1500 mm3 and platelet count \> 100,000 mm3~* Normal myocardial left ventricular function~* Serum creatinine \< 2.0 mg/dl~* Total bilirubin and AST \< 3X upper limits normal~Exclusion Criteria:~* Recurrent or metastatic breast cancer findings (Note: If oncologically felt to be a second breast primary, patient eligible for this protocol)~* Another active cancer present~* Medical contraindications to chemotherapy or surgery~* First trimester pregnancy~* Breast feeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant metronomic AC followed by weekly TC (Type: EXPERIMENTAL): Neoadjuvant chemotherapy with metronomic AC followed by weekly TC then surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).